Edluar receives FDA approval

The US Food and Drug Administration (FDA) has approved Edluar (formerly Sublinox) for the short-term treatment of insomnia. The product contains the well-known substance zolpidem and uses Orexo’s patented sublingual tablet formulation. The collaboration agreement with Orexo entitles them to a milestone payment at FDA approval. That milestone is 5 MUSD based on the product labelling. No further milestone payments for Edluar are expected to be due Orexo. Product launch in the US is anticipated to start during 2nd half of 2009.

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Documents & Links